Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR19396] to Argininosuccinate Lyase
  • Suitable for: WB, IP
  • Reacts with: Mouse, Rat, Human

Overview

  • Product name

    Anti-Argininosuccinate Lyase antibody [EPR19396]
    See all Argininosuccinate Lyase primary antibodies

  • Description

    Rabbit monoclonal [EPR19396] to Argininosuccinate Lyase

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    IP
    Human
    WB
    Mouse
    Rat
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • WB: Human fetal liver and testis lysates; HepG2, T-47D, A549, SH-SY5Y, C6, RAW 264.7, PC-12 and NIH/3T3 whole cell lysates; Mouse and Rat liver lysates. IP: Human fetal liver whole cell lysate.

  • General notes

     

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Images

  • Western blot - Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)
    Western blot - Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)
    All lanes : Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026) at 1/5000 dilution

    Lane 1 : Human fetal liver lysate
    Lane 2 : Human testis lysate
    Lane 3 : HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate
    Lane 4 : T-47D (Human ductal breast epithelial tumor cell line) whole cell lysate
    Lane 5 : Mouse liver lysate
    Lane 6 : Rat liver lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution

    Predicted band size: 51 kDa



    Blocking/Dilution buffer: 5% NFDM/TBST.

    Exposure time: Lane 1: 2 seconds; Lane 2: 1 minute; Lane 3 and 4: 5 seconds; Lane 5 and 6: 1 second.

  • Western blot - Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)
    Western blot - Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)
    All lanes : Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026) at 1/2000 dilution

    Lane 1 : A549 (Human lung carcinoma cell line) whole cell lysate
    Lane 2 : SH-SY5Y (Human neuroblastoma cell line from bone marrow) whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Predicted band size: 51 kDa
    Observed band size: 51 kDa


    Exposure time: 1 minute


    Blocking/Dilution buffer: 5% NFDM/TBST.

  • Western blot - Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)
    Western blot - Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)
    All lanes : Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026) at 1/2000 dilution

    Lane 1 : C6 (Rat glial tumor cell line) whole cell lysate
    Lane 2 : RAW 264.7 (Mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate
    Lane 3 : PC-12 (Rat adrenal gland pheochromocytoma cell line) whole cell lysate
    Lane 4 : NIH/3T3 (Mouse embryonic fibroblast cell line) whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Predicted band size: 51 kDa
    Observed band size: 51 kDa


    Exposure time: 15 seconds


    Blocking/Dilution buffer: 5% NFDM/TBST.

  • Western blot - Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)
    Western blot - Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)
    All lanes : Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026) at 1/5000 dilution

    Lane 1 : Human fetal liver lysate
    Lane 2 : Human fetal lung lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution

    Predicted band size: 51 kDa
    Observed band size: 51 kDa


    Exposure time: 2 seconds


    Blocking/Dilution buffer: 5% NFDM/TBST.

    Argininosuccinate Lyase is predominantly expressed in the liver, and weakly expressed in the lung (PMID: 8576237).

  • Immunoprecipitation - Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)
    Immunoprecipitation - Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)

    Argininosuccinate Lyase was immunoprecipitated from 0.35 mg of Human fetal liver whole cell lysate with ab201026 at 1/30 dilution.

    Western blot was performed from the immunoprecipitate using ab201026 at 1/1000 dilution.

    VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.

    Lane 1: Human fetal liver whole cell lysate, 10µg (Input).

    Lane 2: ab201026 IP in Human fetal liver whole cell lysate.

    Lane 3: Rabbit IgG,monoclonal [EPR25A]-Isotype Control (ab172730) instead of ab201026 in Human fetal liver whole cell lysate.

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 1 second.

  • Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)
    Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-Argininosuccinate Lyase antibody [EPR19396] (ab201026)

© 2021 Astana Biomed Group LLP. All rights reserved.